Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function

Endocrine

Volumn 51, Issue 3, 2016, Pages 429-439

  Morita, Asuka ^a   Mukai, Eri ^a   Hiratsuka, Ayano ^a   Takatani, Tomozumi ^a   Iwanaga, Toshihiko ^b   Lee, Eun Young ^a   Miki, Takashi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; DPP 4 inhibitor; GLP 1 receptor agonist; Glucose tolerance; Insulin secretion; cell proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPHTHERIA TOXIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; INSULIN; LIRAGLUTIDE; MK 0626; UNCLASSIFIED DRUG; EXENDIN (9-39); GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MK0626; PEPTIDE FRAGMENT; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL PROTECTION; CELL REGENERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE TOLERANCE; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; AGONISTS; ANATOMY AND HISTOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; DRUG EFFECTS; METABOLISM; PANCREAS FUNCTION TEST; REGENERATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL DEATH; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; LIRAGLUTIDE; MICE; PANCREATIC FUNCTION TESTS; PEPTIDE FRAGMENTS; REGENERATION; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84959480518     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0733-4     Document Type: Article

References (34)

1. F. Ismail-Beigi, Clinical practice. Glycemic management of type 2 diabetes mellitus. N. Engl. J. Med. 366, 1319–1327 (2012). doi:10.1056/NEJMcp1013127
2. UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998)
3. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, B.G. Kravitz, J.M. Lachin, M.C. O’Neill, B. Zinman, G. Viberti, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443 (2006). doi:10.1056/NEJMoa066224
4. UK Prospective Diabetes Study Group, UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44, 1249–1258 (1995)
5. H. Sakuraba, H. Mizukami, N. Yagihashi, R. Wada, C. Hanyu, S. Yagihashi, Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45, 85–96 (2002). doi:10.1007/s001250200009
6. A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, P.C. Butler, Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102–110 (2003)
7. K.H. Yoon, S.H. Ko, J.H. Cho, J.M. Lee, Y.B. Ahn, K.H. Song, S.J. Yoo, M.I. Kang, B.Y. Cha, K.W. Lee, H.Y. Son, S.K. Kang, H.S. Kim, I.K. Lee, S. Bonner-Weir, Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J. Clin. Endocrinol. Metab. 88, 2300–2308 (2003). doi:10.1210/jc.2002-020735
8. J. Rahier, Y. Guiot, R.M. Goebbels, C. Sempoux, J.C. Henquin, Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes. Metab. 10(Suppl 4), 32–42 (2008). doi:10.1111/j.1463-1326.2008.00969.x
9. M.A. Nauck, Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am. J. Med. 124, S3–S18 (2011). doi:10.1016/j.amjmed.2010.11.002
10. J.E. Campbell, D.J. Drucker, Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819–837 (2013). doi:10.1016/j.cmet.2013.04.008
11. M. Saito, T. Iwawaki, C. Taya, H. Yonekawa, M. Noda, Y. Inui, E. Mekada, Y. Kimata, A. Tsuru, K. Kohno, Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat. Biotechnol. 19, 746–750 (2001)
12. K. Kaneko, K. Ueki, N. Takahashi, S. Hashimoto, M. Okamoto, M. Awazawa, Y. Okazaki, M. Ohsugi, K. Inabe, T. Umehara, M. Yoshida, M. Kakei, T. Kitamura, J. Luo, R.N. Kulkarni, C.R. Kahn, H. Kasai, L.C. Cantley, T. Kadowaki, Class IA phosphatidylinositol 3-kinase in pancreatic beta cells controls insulin secretion by multiple mechanisms. Cell Metab. 12, 619–632 (2010). doi:10.1016/j.cmet.2010.11.005
13. T. Ohyama, K. Sato, Y. Yamazaki, H. Hashizume, N. Horiguchi, S. Kakizaki, M. Mori, M. Kusano, M. Yamada, MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice. World J. Gastroenterol. 20, 16227–16235 (2014). doi:10.3748/wjg.v20.i43.16227
14. J.H. Ellenbroek, H.A. Tons, N. de Graaf, M.A. Hanegraaf, T.J. Rabelink, F. Carlotti, E.J. de Koning, Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia 56, 1980–1986 (2013). doi:10.1007/s00125-013-2957-2
15. D.D. De Leon, S. Deng, R. Madani, R.S. Ahima, D.J. Drucker, D.A. Stoffers, Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52, 365–371 (2003)
16. E. Mukai, T. Ohta, H. Kawamura, E.Y. Lee, A. Morita, T. Sasase, K. Miyajima, N. Inagaki, T. Iwanaga, T. Miki, Enhanced vascular endothelial growth factor signaling in islets contributes to beta cell injury and consequential diabetes in spontaneously diabetic Torii rats. Diabetes Res. Clin. Pract. 106, 303–311 (2014). doi:10.1016/j.diabres.2014.08.023
17. T. Miki, K. Nagashima, F. Tashiro, K. Kotake, H. Yoshitomi, A. Tamamoto, T. Gonoi, T. Iwanaga, J. Miyazaki, S. Seino, Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc. Natl. Acad. Sci. USA 95, 10402–10406 (1998)
18. J. Miyazaki, K. Araki, E. Yamato, H. Ikegami, T. Asano, Y. Shibasaki, Y. Oka, K. Yamamura, Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127, 126–132 (1990). doi:10.1210/endo-127-1-126
19. A. Iwama, H. Oguro, M. Negishi, Y. Kato, Y. Morita, H. Tsukui, H. Ema, T. Kamijo, Y. Katoh-Fukui, H. Koseki, M. van Lohuizen, H. Nakauchi, Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21, 843–851 (2004). doi:10.1016/j.immuni.2004.11.004
20. E. Mukai, S. Fujimoto, H. Sato, C. Oneyama, R. Kominato, Y. Sato, M. Sasaki, Y. Nishi, M. Okada, N. Inagaki, Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 60, 218–226 (2011). doi:10.2337/db10-0021
21. C. Postic, M. Shiota, K.D. Niswender, T.L. Jetton, Y. Chen, J.M. Moates, K.D. Shelton, J. Lindner, A.D. Cherrington, M.A. Magnuson, Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274, 305–315 (1999)
22. N. Komatsu, T. Oda, T. Muramatsu, Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and pseudomonas toxin. J. Biochem. 124, 1038–1044 (1998)
23. D.R. McIlwain, T. Berger, T.W. Mak, Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 5, a008656 (2013). doi:10.1101/cshperspect.a008656
24. J.Y. Lee, M. Ristow, X. Lin, M.F. White, M.A. Magnuson, L. Hennighausen, RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J. Biol. Chem. 281, 2649–2653 (2006)
25. K. Oyama, K. Minami, K. Ishizaki, M. Fuse, T. Miki, S. Seino, Spontaneous recovery from hyperglycemia by regeneration of pancreatic beta-cells in Kir6.2G132S transgenic mice. Diabetes 55, 1930–1938 (2006). doi:10.2337/db05-1459
26. Y. Dor, J. Brown, O.I. Martinez, D.A. Melton, Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429, 41–46 (2004). doi:10.1038/nature02520
27. T. Nir, D.A. Melton, Y. Dor, Recovery from diabetes in mice by beta cell regeneration. J. Clin. Invest. 117, 2553–2561 (2007)
28. Q. Wang, P.L. Brubaker, Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45, 1263–1273 (2002). doi:10.1007/s00125-002-0828-3
29. T. Tomita, Immunocytochemical localisation of caspase-3 in pancreatic islets from type 2 diabetic subjects. Pathology 42, 432–437 (2010). doi:10.3109/00313025.2010.493863
30. Y. Lee, E.D. Berglund, M.Y. Wang, X. Fu, X. Yu, M.J. Charron, S.C. Burgess, R.H. Unger, Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc. Natl. Acad. Sci. USA 109, 14972–14976 (2012). doi:10.1073/pnas.1205983109
31. C. Talchai, S. Xuan, H.V. Lin, L. Sussel, D. Accili, Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150, 1223–1234 (2012). doi:10.1016/j.cell.2012.07.029
32. D. Yabe, Y. Seino, Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog. Biophys. Mol. Biol. 107, 248–256 (2011). doi:10.1016/j.pbiomolbio.2011.07.010
33. Y. Sakurai, N. Shintani, A. Hayata, H. Hashimoto, A. Baba, Trophic effects of PACAP on pancreatic islets: a mini-review. J. Mol. Neurosci. 43, 3–7 (2011). doi:10.1007/s12031-010-9424-z
34. R. Violante, J.H. Oliveira, K.H. Yoon, V.A. Reed, M.B. Yu, O.P. Bachmann, J. Ludemann, J.Y. Chan, A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet. Med. 29, e417–e424 (2012). doi:10.1111/j.1464-5491.2012.03624.x